Jul
Medical Patent News
India’s Patent Office in New Delhi earlier this month rejected German drug maker Boehringer Ingelheim’s application for a pediatric version of the antiretroviral drug nevirapine, consequently allowing local generic pharmaceutical companies such as Aurobindo and Cipla to continue marketing low-cost versions of the medicine in the domestic market, the Business Standard reports.
The decision follows objections to the potential patent from civil society groups in the country (Mathew, Business Standard, 6/20).
According to the Lawyer’s Collective, a New Delhi-based socio-legal group, this is the first decision width=396 align=left vspace=5 border=0>This article is republished with kind permission from our friends at The Kaiser Family Foundation. You can view the entire Kaiser Daily Health Policy Report, search the archives, or sign up for email delivery of in-depth coverage of health policy developments, debates and discussions. The Kaiser Daily Health Policy Report is published for Kaisernetwork.org, a free service of The Henry J. Kaiser Family Foundation. Copyright 2008 Advisory Board Company and Kaiser Family Foundation. All rights reserved.